OBJECTIVE: To assess HIV vaccine acceptability among high-risk adults in Los Angeles. STUDY SETTING: Sexually transmitted disease clinics, needle/syringe exchange programs, Latino community health/HIV prevention programs. STUDY DESIGN: Cross-sectional survey using conjoint analysis. Participants were randomly selected using three-stage probability sampling. DATA COLLECTION: Sixty-minute structured interviews. Participants rated acceptability of eight hypothetical vaccines, each with seven dichotomous attributes, and reported post-vaccination risk behavior intentions. PRINCIPAL FINDINGS: Participants (n=1164; 55.7 percent male, 82.4 percent ethnic minority, mean age=37.4 years) rated HIV vaccine acceptability from 28.4 to 88.6; mean=54.5 (SD=18.8; 100-point scale). Efficacy had the greatest impact on acceptability, followed by side effects and out-of-pocket cost. Ten percent would decrease condom use after vaccination. CONCLUSIONS: Findings support development of social marketing interventions to increase acceptability of "partial efficacy" vaccines, behavioral interventions to mitigate risk compensation, and targeted cost subsidies.
OBJECTIVE: To assess HIV vaccine acceptability among high-risk adults in Los Angeles. STUDY SETTING: Sexually transmitted disease clinics, needle/syringe exchange programs, Latino community health/HIV prevention programs. STUDY DESIGN: Cross-sectional survey using conjoint analysis. Participants were randomly selected using three-stage probability sampling. DATA COLLECTION: Sixty-minute structured interviews. Participants rated acceptability of eight hypothetical vaccines, each with seven dichotomous attributes, and reported post-vaccination risk behavior intentions. PRINCIPAL FINDINGS:Participants (n=1164; 55.7 percent male, 82.4 percent ethnic minority, mean age=37.4 years) rated HIV vaccine acceptability from 28.4 to 88.6; mean=54.5 (SD=18.8; 100-point scale). Efficacy had the greatest impact on acceptability, followed by side effects and out-of-pocket cost. Ten percent would decrease condom use after vaccination. CONCLUSIONS: Findings support development of social marketing interventions to increase acceptability of "partial efficacy" vaccines, behavioral interventions to mitigate risk compensation, and targeted cost subsidies.
Authors: Edward Mills; Curtis Cooper; Gordon Guyatt; Amy Gilchrist; Beth Rachlis; Chris Sulway; Kumanan Wilson Journal: AIDS Date: 2004-11-19 Impact factor: 4.177
Authors: William E Cunningham; Ron D Hays; Naihua Duan; Ronald Andersen; Terry T Nakazono; Samuel A Bozzette; Martin F Shapiro Journal: J Health Care Poor Underserved Date: 2005-11
Authors: Antoine Messiah; Aymery Constant; Benjamin Contrand; Marie-Line Felonneau; Emmanuel Lagarde Journal: Am J Public Health Date: 2012-05 Impact factor: 9.308
Authors: Jennifer D Allen; Gloria D Coronado; Rebecca S Williams; Beth Glenn; Cam Escoffery; Maria Fernandez; Raegan A Tuff; Katherine M Wilson; Patricia Dolan Mullen Journal: Vaccine Date: 2010-04-20 Impact factor: 3.641
Authors: Ingrid T Katz; Norma C Ware; Glenda Gray; Jessica E Haberer; Claude A Mellins; David R Bangsberg Journal: Sex Health Date: 2010-09 Impact factor: 2.706